Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors

Pharmaceuticals

Volumn 7, Issue 12, 2014, Pages 1049-1068

  Fujiwara, Hiroshi ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adoptive immunotherapy; Chimeric antigen receptor; Gene modified T cell; Hematological malignancy; T cell receptor

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; FLUDARABINE; MELAN A; MELANOMA ANTIGEN 3; MELPHALAN; NY ESO 1 ANTIGEN; SMALL INTERFERING RNA; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TOCILIZUMAB; ZINC FINGER NUCLEASE;

ADOPTIVE IMMUNOTHERAPY; AMINO ACID SUBSTITUTION; ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CARDIOGENIC SHOCK; CARDIOTOXICITY; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CIRCULATING TUMOR CELL; COLITIS; CONSCIOUSNESS DISORDER; CYTOKINE RELEASE SYNDROME; DONOR LYMPHOCYTE INFUSION; DRUG FATALITY; DRUG RESPONSE; EAR DISEASE; EFFECTOR CELL; EYE DISEASE; FEVER; GENE EXPRESSION; GENE MUTATION; HEART DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOTENSION; HYPOXIA; INFECTION; KIDNEY FAILURE; LEIGH DISEASE; LUNG INSUFFICIENCY; LYMPHOCYTOPENIA; MACROPHAGE ACTIVATION SYNDROME; MELANOMA; MENTAL DISEASE; MYELOMA; NEUROLOGIC DISEASE; NONHUMAN; REVIEW; RISK FACTOR; SKIN DISEASE; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR LYSIS SYNDROME; TUMOR REGRESSION;

EID: 84919795391     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph7121049     Document Type: Review

References (87)

1. Miller, J.S.; Warren, E.H.; van den Brink, M.R.; Ritz, J.; Shlomchik, W.D.; Murphy, W.J.; Barrett, A.J.; Kolb, H.J.; Giralt, S.; Bishop, M.R.;et al. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol. Blood Marrow Transplant. 2010, 16, 565-586.
2. Blyth, E.; Clancy, L.; Simms, R.; Ma, C.K.; Burgess, J.; Deo, S.; Byth, K.; Dubosq, M.C.; Shaw, P.J.; Michlethwaite K.P.;et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood2013, 121, 3745-3758.
3. Rosenberg,S.A.; Dudley, M.E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol.2009, 21, 233-240.
4. Dudley, M.E.; Yang, J.C.; Sherry, R.; Hughes, M.S.; Royal, R.; Kammula, U.; Robbins P.F.; Huang, J.; Citrin, D.E.; Leitman, S.F.;et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26, 5233-5239.
5. +T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 2010, 70, 6725-6734.
6. Muranski, P.; Boni, A.; Wrzesinski, C.; Citrin, D.E.; Rosenberg, S.A.; Childs, R.; Restifo, N.P. Increased intensity lymphodepletionand adoptive immunotherapy-How far can we go?Nat. Clin. Pract. Oncol. 2006, 3, 668-681.
7. Miller, J.S.; Soignier, Y.; Panoskaltsis-Mortari, A.; McNearney, S.A.; Yun, G.H.; Fautsch, S.K.; McKenna, D.; Le, C.; Defor, T.E.; Burns, L.J.;et al. Successful adoptive transfer andin vivoexpansion of human haploidentical NK cells in patients with cancer. Blood2005, 105, 3051-3057.
8. Ferrara,J.L.; Levine, J.E.; Reddy, P.; Holler, E. Graft-versus-host disease. Lancet2009, 373, 1550-1561.
9. Besser, M.J.; Shapira-Frommer, R.; Treves, A.J.; Zippel, D.; Itzhaki, O.; Schallmach, E.; Kubi, A.; Shalmon, B.; Hardan, I.; Catane, R.;et al. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.J. Immunother. 2009, 32, 415-423.
10. Vincent, K.;Roy, D.C.; Perreault, C. Next-generation leukemia immunotherapy. Blood2011, 118, 2951-2959.
11. Jamieson, B.D.; Ahmed, R. T cell memory. Long-term persistence of virus-specific cytotoxic T cells. J. Exp. Med. 1989, 169, 1993-2005.
12. Michie, C.A.; McLean, A.; Alcock, C.; Beverly, P.C. Lifespan of human lymphocyte subsets defined by CD45 isoform. Nature 1992, 360, 264-265.
13. Koya, R.C.; Mok, S.; Comin-Anduix, B Chodon, T.; Radu, C.G.; Nishimura, M.I.; Witte, O.N.; Ribas, A. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc. Natl. Acad. Sci.USA2010, 107, 14286-14291.
14. Hildebrandt, M.; Peggs, K.; Uharek, L.; Bollard, C.M.; Heslop, H.E. Immunotherapy: Opportunities, risks and future perspectives. Cytotherapy 2014, 16, S120-S129.
15. Park, T.S.; Rosenberg,S.A.; Morgan, R.A. Treating cancer with genetically engineered T cells. Trends Biotechnol. 2011, 29, 550-557.
16. Ochi, T.; Fujiwara, H.; Yasukawa, M. Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer. Expert Opin. Biol. Ther. 2011, 11, 699-713.
17. Au, P.; Hursh, D.A.; Lim, A.; Moos, M.C. Jr.; Oh, S.S.; Schneider, B.S.; Witten, C.M. FDA oversight of cell therapy clinical trials. Sci. Transl. Med. 2012, 4, 49fs31.
18. Fujiwara, H. Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. Int. J. Hematol. 2014, 99, 123-131.
19. Corrigan-Curay, J.; Kiem, H.P.; Baltimore, D.; O'Reilly, M.; Brentjens, R.J.; Cooper, L.; Forman, S.; Gottschalk, S.; Greenberg, P.; Junghans, R.; et al. T-cell immunotherapy: Looking forward. Mol. Ther. 2014, 22, 1564-1574.
20. June, C.H. Principles of adoptive T cell cancer therapy. J. Clin. Inv. 2007, 117, 1204-1212.
21. Schmitt, T.M.; Aggen, D.H.; Stromnes, I.M.; Dossett, M.L.; Richman, S.A.; Kranz, D.M.; Greenberg, P.D. Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood2013, 122, 348-356.
22. Li, Y.; Moysey, R.;Molloy, P.E.; Vuidepot, A.L.;Mahon, T.; Baston, E.; Dunn, S.; Liddy, N.; Jacob, J.; Jakobsen, B.K.;et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 2005, 23, 349-354.
23. Stauss, H.J. Immunotherapy with CTLs restricted by nonself MHC. Immunol. Today1999, 20, 180-183.
24. Stanislawski, T.; Voss, R.H.;Lotz, C.; Sadovnikova, E.; Willemsen, R.A.; Kuball, J.; Ruppert, T.; Bolhuis, R.L.; Melief, C.J.; Huber, C.;et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2001, 2, 962-970.
25. Morgan, R.A.; Chinnasamy, N.; Abate-Daga, D.; Gros, A.; Robbins, P.F.; Zheng, Z.; Dudley, M.E.; Feldman, S.A.; Yang, J.C.; Sherry, R.M.;et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 2013, 36, 133-151.
26. Linette, G.P.; Stadtmauer, E.A.; Maus, M.V.; Rapoport,A.P.; Levine, B.L.; Emery, L.;Litzky, L.; Bagg, A.; Carreno, B.M.; Cimino, P.J.;et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013, 122, 863-871.
27. Johnson, L.A.; Morgan, R.A.; Dudley, M.E.; Cassard, L.; Yang, J.C.; Hughes, M.S.; Kammula, U.S.; Royal, R.E.; Sherry, R.M.; Wunderlich J.R.;et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood2009, 114, 535-546.
28. Parkhurst, M.R.; Yang, J.C.; Langan, R.C.; Dudley, M.E.; Nathan, D.A.; Feldman, S.A.; Davis, J.L.; Morgan, R.A.; Merino, M.J.; Sherry, M.R.;et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 2011, 19, 620-626.
29. Robbins, P.F.; Morgan, R.A.; Feldman, S.A.; Yang, J.C.; Sherry, R.M.; Dudley, M.E.; Wunderlich, J.R.; Nahvi, A.V.; Helman, L.J.; Mackall, C.L.;et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol.2011, 29, 917-924.
30. Cohen, C.J.; Li, Y.F.; El-Gamil, M.; Robbins, P.F.; Rosenberg, S.A.; Morgan, R.A. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 2007, 67, 3898-3903.
31. Thomas, S.;Xue, S.A.; Cesco-Gaspere, M.; San José, E.; Hart, D.P.; Wong, V.; Debets, R.; Alarcon, B.; Morris, E.; Stauss, H.J. Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J. Immunol.2007, 179, 5803-5810.
32. Bendle, G.M.; Linnemann, C.;Hooijkaas, A.I.; Bies, L.; de Witte, M.A.; Jorritsma, A.; Kaiser, A.D.; Pouw, N.; Debets, R.; Kieback, E.;et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 2010, 16, 565-570.
33. Okamoto, S.; Mineno, J.; Ikeda, H.; Fujiwara, H.; Yasukawa, M.; Shiku, H.; Kato, I. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 2009, 69, 9003-9011.
34. Okamoto, S.; Amaishi, Y.; Goto, Y.; Ikeda, H.; Fujiwara, H.; Kuzushima, K.; Yasukawa, M.; Shiku, H.; Mineno, J. A Promising Vector for TCR Gene Therapy: Differential Effect of siRNA, 2A Peptide, and Disulfide Bond on the Introduced TCR Expression. Mol. Ther. Nucleic Acids2012, 1, e63.
35. Provasi, E.; Genovese, P.; Lombardo, A.; Magnani, Z.; Liu, P.Q.; Reik, A.; Chu, V.; Paschon, D.E.; Zhang, L.; Kuball, J.;et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012, 18, 807-815.
36. Torikai, H.; Reik, A.; Liu, P.Q.; Zhou, Y.; Zhang, L.; Maiti, S.; Huls, H.; Miller, J.C.; Kebriaei, P.; Rabinovitch, B.;et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptorand eliminate expression of endogenous TCR. Blood2012, 119, 5697-5705.
37. Morgan, R.A.; Dudley, M.E.; Wunderlich, J.R.; Hughes, M.S.; Yang, J.C.; Sherry, R.M.; Royal, R.E.; Topalian, S.L.; Kammula, U.S.; Restifo, N.P.;et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science2006, 314, 126-129.
38. Davis,J.L.; Theoret, M.R.; Zheng, Z.; Lamers, C.H.; Rosenberg, S.A.; Morgan, R.A. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin. Cancer Res.2010, 16, 5852-5861.
39. Ochi, T.; Fujiwara, H.; Okamoto, S.; An, J.; Nagai, K.; Shirakata, T.; Mineno, J.; Kuzushima, K.; Shiku, H.; Yasukawa, M. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. Blood2011, 118, 1495-1503.
40. Tebas, P.; Stein, D.; Tang, W.W.; Frank, I.; Wang, S.Q.; Lee, G.; Spratt, S.K.; Surosky, R.T.; Giedlin, M.A.; Nichol, G.;et al. Gene editing of CCR5in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 2014, 370, 901-910.
41. Sadelain, M.; Brentjens, R.; Rivière, I. The basic principles of chimericantigen receptordesign. Cancer Discov. 2013, 3, 388-398.
42. Irving, B.A.; Weiss, A. The cytoplasmic domain of the T cellreceptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell1991, 64, 891-901.
43. Eshhar, Z.; Waks, T.; Gross, G.; Schindler, D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 1993, 90, 720-724.
44. Gong, M.C.; Latouche, J.B.; Krause, A.; Heston, W.D.; Bander, N.H.; Sadelain, M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia1999, 1, 123-127.
45. Haynes, N.M.; Trapani, J.A.; Teng, M.W.; Jackson, J.T.; Cerruti, L.; Jane, S.M.; Kershaw, M.H.; Smyth, M.J.; Darcy, P.K. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J. Immunol. 2002, 169, 5780-5786.
46. Carpenito, C.; Milone, M.C.; Hassan, R.; Simonet, J.C.; Lakhal, M.; Suhoski, M.M.; Varela-Rohena, A.; Haines, K.M.; Heitjan, D.F.; Albelda, S.M.;et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137domains. Proc. Natl. Acad. Sci.USA2009, 106, 3360-3365.
47. Hombach, A.A.; Abken, H. Costimulation by chimeric antigen receptorsrevisited the T cell antitumor response benefits from combined CD28-OX40signalling. Int. J. Cancer. 2011, 129, 2935-2944.
48. Finney, H.M.; Akbar, A.N.; Lawson, A.D. Activation of resting human primary T cells with chimericreceptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J. Immunol. 2004, 172, 104-113.
49. Finney, H.M.; Lawson, A.D.; Bebbington, C.R.; Weir, A.N. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 1998, 161, 2791-2797.
50. Hombach, A.; Wieczarkowiecz, A.; Marquardt, T.; Heuser, C.; Usai, L.; Pohl, C.; Seliger, B.; Abken, H. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J. Immunol. 2001, 167, 6123-6131.
51. Kalos, M.; Levine, B.L.; Porter, D.L.; Katz, S.; Grupp, S.A.; Bagg, A.; June, C.H. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.Sci. Transl. Med. 2011, 3, 95ra73.
52. Porter, D.L.; Levine, B.L.; Kalos, M.; Bagg, A.; June, C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med.2011, 365, 725-733.
53. Kochenderfer, J.N.; Wilson, W.H.; Janik, J.E.; Dudley, M.E.; Stetler-Stevenson, M.; Feldman, S.A.; Maric, I.; Raffeld, M.; Nathan, D.A.; Lanier, B.J.;et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood2010, 116, 4099-4102.
54. Brentjens, R.J.; Davila, M.L.; Riviere, I.; Park, J.; Wang, X.; Cowell, L.G.; Bartido, S.; Stefanski, J.; Taylor, C.; Olszewska, M.; et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 2013, 5, 177ra38.
55. Jensen, M.C.; Popplewell, L.; Cooper, L.J.; DiGiusto, D.; Kalos, M.; Ostberg, J.R.; Forman, S.J. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol. BloodMarrow Transplant.2010, 16, 1245-1256.
56. Davila, M.L.; Riviere, I.; Wang, X.; Bartido, S.; Park, J.; Curran, K.; Chung, S.S.; Stefanski, J.; Borquez-Ojeda, O.; Olszewska, M.;et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 2014, 6, 224ra25.
57. Gilham, D.E.; Debets, R.; Pule, M.; Hawkins, R.E.; Abken, H. T cells and solid tumors: Tuning T cells to challenge an inveterate foe. Trends Mol. Med. 2012, 18, 377-384.
58. Davila, M.L.; Brentjens, R.; Wang, X.; Rivière, I.; Sadelain, M. How do CARs work? : Early insights from recent clinical studies targeting CD19. Oncoimmunology2012, 1, 1577-1583.
59. Kochenderfer, J.N.; Dudley, M.E.; Feldman, S.A.; Wilson, W.H.; Spaner, D.E.; Maric, I.; Stetler-Stevenson, M.; Phan, G.Q.; Hughes, M.S.; Sherry, R.M.;et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood2012, 119, 2709-2720.
60. Savoldo, B.; Ramos, C.A.; Liu, E.; Mims, M.P.; Keating, M.J.; Carrum, G.; Kamble, R.T.; Bollard, C.M.; Gee, A.P.; Mei, Z.; et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 2011, 121, 1822-1826.
61. Grupp, S.A.; Kalos, M.; Barrett, D.; Aplenc, R.; Porter, D.L.; Rheingold, S.R.; Teachey, D.T.; Chew, A.; Hauck, B.; Wright, J.F.;et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013, 368, 1509-1518.
62. Chmielewski, M.; Hombach, A.; Heuser, C.; Adams, G.P.; Abken, H. T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J. Immunol. 2004, 173, 7647-7653.
63. Long, A.H.; Haso, W.M.; Orentas, R.J. Lessons learned from a highly-active CD22-specific chimeric antigen receptor. Oncoimmunology2013, 2, e23621.
64. Park,J.R.; Digiusto, D.L.; Slovak, M.; Wright, C.; Naranjo, A.; Wagner, J.; Meechoovet, H.B.; Bautista, C.; Chang, W.C.; Ostberg, J.R.;et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 2007, 15, 825-833.
65. Morgan, R.A.; Yang, J.C.; Kitano, M.; Dudley, M.E.; Laurencot, C.M.; Rosenberg, S.A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 2010, 18, 843-851.
66. Louis, C.U.; Savoldo, B.; Dotti, G.; Pule, M.; Yvon, E.; Myers, G.D.; Rossig, C.; Russell, H.V.; Diouf, O.; Liu, E.;et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood2011, 118, 6050-6056.
67. Till,B.G.; Jensen, M.C.; Wang, J.; Qian, X.; Gopal, A.K.; Maloney, D.G.; Lindgren, C.G.; Lin, Y.; Pagel, J.M.; Budde, L.E.;et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: Pilot clinical trial results. Blood2012, 119, 3940-3950.
68. Cheadle, E.J.; Sheard, V.; Rothwell, D.G.; Mansoor, A.W.; Hawkins, R.E.; Gilham, D.E. Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model. J. Immunol. 2014, 192, 3654-3665.
69. +T cells can mediate antileukemicactivity and persist in post-transplant patients. Sci. Transl. Med. 2013, 5, 174ra27.
70. Valitutti, S.; Lanzavecchia, A. Serial triggering of TCRs: A basis for the sensitivity and specificity of antigen recognition. Immunol. Today. 1997, 18, 299-304.
71. Alexander-Miller, M.A.; Leggatt, G.R.; Berzofsky, J.A. Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci.USA1996, 93, 4102-4107.
72. Nakamura, M.; Oda, S.; Sadahiro, T.; Hirayama, Y.; Tateishi, Y.; Abe, R.; Hirasawa, H. The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome(TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF).Transfus. Apher. Sci. 2009, 40, 41-47.
73. Brentjens, R.; Yeh, R.; Bernal, Y.; Riviere, I.; Sadelain, M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 2010, 18, 666-668.
74. Maus, M.V.; Haas, A.R.; Beatty, G.L.; Albelda, S.M.; Levine, B.L.; Liu, X.; Zhao, Y.; Kalos, M.; June C.H. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 2013, 1, 26-31.
75. Robbins, P.F.; Lu, Y.C.; El-Gamil, M.; Li, Y.F.; Gross, C.; Gartner, J.; Lin, J.C.; Teer, J.K.; Cliften, P.; Tycksen, E.;et al. Mining exomic sequencing data to identify mutatedantigensrecognized by adoptively transferred tumor-reactive T cells. Nat. Med. 2013, 19, 747-752.
76. Snauwaert, S.; Vandekerckhove, B.; Kerre, T. Can immunotherapy specifically target acute myeloid leukemic stem cells? Oncoimmunology2013, 2, e22943.
77. Ciceri, F.; Bonini, C.; Stanghellini, M.T.; Bondanza, A.; Traversari, C.; Salomoni, M.; Turchetto, L.; Colombi, S.; Bernardi, M.; Peccatori, J.;et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): Anon-randomised phase I-II study. Lancet Oncol. 2009, 10, 489-500.
78. Di Stasi, A.; Tey, S.K.; Dotti, G.; Fujita, Y.; Kennedy-Nasser, A.; Martinez, C.; Straathof, K.; Liu, E.; Durett, A.G.; Grilley, B.;et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 2011, 365, 1673-1683.
79. +T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 2008, 118, 294-305.
80. +T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci.USA2009, 106, 17469-17474.
81. Butler, M.O.; Hirano, N. Human cell-based artificial antigen-presenting cells for cancer immunotherapy.Immunol. Rev. 2013, 257, 191-209.
82. Hodi, F.S.; O'Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.;et al. Improved survival with ipilimumabin patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711-723.
83. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.;et al. Safety, activity, and immune correlates of anti-PD-1antibody in cancer. N. Engl. J. Med. 2012, 366, 2443-2454.
84. Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.;et al. Safety and activity of anti-PD-L1antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366, 2455-2465.
85. Abate-Daga, D.; Hanada, K.; Davis, J.L.; Yang, J.C.; Rosenberg, S.A.; Morgan, R.A. Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood2013, 122, 1399-1410.
86. Day, C.L.; Kaufmann, D.E.; Kiepiela, P.; Brown, J.A.; Moodley, E.S.; Reddy, S.; Mackey, E.W.; Miller, J.D.; Leslie, A.J.; De Pierres, C.;et al. PD-1expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature2006, 443, 350-354.
87. Moon, E.K.; Wang, L.C.; Dolfi, D.V.; Wilson, C.B.; Ranganathan, R.; Sun, J.; Kapoor, V.; Scholler, J.; Puré, E.; Milone, M.C.;et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin. Cancer Res. 2014, 20, 4262-4273.